325 related articles for article (PubMed ID: 16145055)
1. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Gianni L; Zambetti M; Clark K; Baker J; Cronin M; Wu J; Mariani G; Rodriguez J; Carcangiu M; Watson D; Valagussa P; Rouzier R; Symmans WF; Ross JS; Hortobagyi GN; Pusztai L; Shak S
J Clin Oncol; 2005 Oct; 23(29):7265-77. PubMed ID: 16145055
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
3. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients.
Chang JC; Makris A; Gutierrez MC; Hilsenbeck SG; Hackett JR; Jeong J; Liu ML; Baker J; Clark-Langone K; Baehner FL; Sexton K; Mohsin S; Gray T; Alvarez L; Chamness GC; Osborne CK; Shak S
Breast Cancer Res Treat; 2008 Mar; 108(2):233-40. PubMed ID: 17468949
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
5. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
[TBL] [Abstract][Full Text] [Related]
6. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue.
Mina L; Soule SE; Badve S; Baehner FL; Baker J; Cronin M; Watson D; Liu ML; Sledge GW; Shak S; Miller KD
Breast Cancer Res Treat; 2007 Jun; 103(2):197-208. PubMed ID: 17039265
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Chang JC; Wooten EC; Tsimelzon A; Hilsenbeck SG; Gutierrez MC; Elledge R; Mohsin S; Osborne CK; Chamness GC; Allred DC; O'Connell P
Lancet; 2003 Aug; 362(9381):362-9. PubMed ID: 12907009
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
Stearns V; Singh B; Tsangaris T; Crawford JG; Novielli A; Ellis MJ; Isaacs C; Pennanen M; Tibery C; Farhad A; Slack R; Hayes DF
Clin Cancer Res; 2003 Jan; 9(1):124-33. PubMed ID: 12538460
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
Ayers M; Symmans WF; Stec J; Damokosh AI; Clark E; Hess K; Lecocke M; Metivier J; Booser D; Ibrahim N; Valero V; Royce M; Arun B; Whitman G; Ross J; Sneige N; Hortobagyi GN; Pusztai L
J Clin Oncol; 2004 Jun; 22(12):2284-93. PubMed ID: 15136595
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
11. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.
Schneider J; Gonzalez-Roces S; Pollán M; Lucas R; Tejerina A; Martin M; Alba A
Breast Cancer Res; 2001; 3(3):183-91. PubMed ID: 11305953
[TBL] [Abstract][Full Text] [Related]
12. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
Hannemann J; Oosterkamp HM; Bosch CA; Velds A; Wessels LF; Loo C; Rutgers EJ; Rodenhuis S; van de Vijver MJ
J Clin Oncol; 2005 May; 23(15):3331-42. PubMed ID: 15908647
[TBL] [Abstract][Full Text] [Related]
13. PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy.
Chen YZ; Xue JY; Chen CM; Yang BL; Xu QH; Wu F; Liu F; Ye X; Meng X; Liu GY; Shen ZZ; Shao ZM; Wu J
Cancer Chemother Pharmacol; 2012 Nov; 70(5):637-44. PubMed ID: 22903535
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy.
Chen Y; Chen C; Yang B; Xu Q; Wu F; Liu F; Ye X; Meng X; Mougin B; Liu G; Shen Z; Shao Z; Wu J
Cancer Lett; 2011 Mar; 302(1):63-8. PubMed ID: 21220187
[TBL] [Abstract][Full Text] [Related]
15. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
16. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
17. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling.
Zembutsu H; Suzuki Y; Sasaki A; Tsunoda T; Okazaki M; Yoshimoto M; Hasegawa T; Hirata K; Nakamura Y
Int J Oncol; 2009 Feb; 34(2):361-70. PubMed ID: 19148470
[TBL] [Abstract][Full Text] [Related]
18. Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Katayama MLH; Vieira RADC; Andrade VP; Roela RA; Lima LGCA; Kerr LM; Campos AP; Pereira CAB; Serio PAMP; Encinas G; Maistro S; Petroni MAL; Brentani MM; Folgueira MAAK
Cells; 2019 Dec; 8(12):. PubMed ID: 31817155
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
[TBL] [Abstract][Full Text] [Related]
20. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
